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http:WHAT THIS PAPER ADDS
Peripheral arterial disease is increasing in prevalence, and it appears that there are differences in the outcomes
between sexes. This paper contradicts previous published data and is unique for two reasons: ﬁrst, it looks at
long-term outcomes on a much wider cohort than those previously reported, and, second, the important role of
prophylactic medical therapy is taken into account.Background: The cardiovascular burden and consequences of peripheral atherosclerosis appear to differ between
men and women. Data regarding long-term outcomes, including the impact of medical prophylactic treatment,
are insufﬁcient. This study examined long-term outcomes according to sex following primary vascular surgery,
adjusted for multiple variables as well as recommended medical prophylaxis.
Methods: All Danish patients who underwent peripheral vascular surgery from January 2000 to December 2007
were stratiﬁed into ﬁve procedural groups: (a) aorto-iliac bypass or thromboendarterectomy, (b) femoroefemoral
crossover, (c) thromboendarterectomy of the femoral arteries, (d) infrainguinal bypass, or (e) axillo- uni-, and
bifemoral bypass. Data were analyzed according to sex for differences in myocardial infarction, stroke, and death,
individually and combined, after surgery.
Results: A total of 11,234 patients were included: 6,289 males and 4,945 females. The overall adjusted hazard
ratio for male patients compared with female patients for death was 1.11 (95% CI 1.06e1.17), for MI was 1.16
(95% CI 1.04e1.29), for stroke was 0.99 (95% CI 0.89e1.11), and for any major adverse cardiovascular event was
1.10 (95% CI 1.05e1.16).
Conclusions: These ﬁndings show that, despite indication, severity, and concomitant medical treatment of
peripheral artery disease, men have a higher risk of mortality and adverse cardiovascular events following surgery
for peripheral arterial disease.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Peripheral artery disease (PAD) is associated with signiﬁcant
morbidity and mortality.1e3 Its relatively high prevalence is
of concern, particularly as the population ages and therresponding author. Department of Vascular Surgery, Aarhus
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//dx.doi.org/10.1016/j.ejvs.2015.08.004incidence of diabetes mellitus and its complications among
PAD patients persist.4 Investigations into the inﬂuence of
sex on PAD have recently intensiﬁed yet, as Hirsch and
colleagues5 point out, there are too many gaps in the evi-
dence to properly deﬁne the differences in the natural
history and outcomes following treatment of PAD between
men and women.
This study looks at the long-term outcomes, speciﬁcally
myocardial infarction (MI), stroke, and survival following
vascular surgery for all patients with symptomatic PAD
requiring surgical intervention. Taking age and several
comorbidities into account, as well as secondary medical
therapy, the aim was to discover differences in outcome
between men and women in a national population
following revascularization.
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Patient group
A retrospective study of the national Danish Vascular Reg-
istry was performed, in which all patients having surgery for
PAD between January 2000 and December 2007 were
included. All operations were primary revascularization
procedures. The Danish Vascular Registry (Karbase) has
nationwide coverage and covers 99.2% of all vascular pro-
cedures performed at Danish hospitals (www.karbase.dk,
annual report 2009). The registry includes data on 65 vari-
ables and has been thoroughly validated.6 It is moreover
cross-linked with the National Population Registry as well as
the National Inpatient Registry, which is used for reim-
bursement. All individuals in Denmark have a unique and
permanent civilian personal register (CPR) code, enabling
complete follow up. All data were entered prospectively.
Approval from the regional ethics committee was obtained
prior to data retrieval.Deﬁnition of variables of interest
Patients were stratiﬁed according to the surgical procedure
performed: (a) aorto-iliac bypass/thromboendarterectomy,
(b) femoro-femoral crossover bypass, (c) thromboendar-
terectomy of the femoral arteries, (d) infrainguinal bypass,
and (e) axillo- uni-, and bifemoral bypass. The indications for
surgery were acute extremity ischemia, claudication, rest
pain, and wound/gangrene of the foot/leg. For purposes of
clariﬁcation, procedural codes in the Danish Vascular Reg-
istry are speciﬁed in terms of indication, that is speciﬁc
codes for revascularization due to PAD or, similarly, codes
for revascularization due to symptomatic aneurysmal dis-
ease or acute thrombosis.
The following patient characteristics were obtained on
admission: body mass index (BMI), creatinine (mmol/L),
tobacco use at the time of surgery, hypertension (previous
diagnosis and/or current antihypertensive medication),
diabetes mellitus, and known pulmonary disease (previous
diagnosis and/or medical treatment). Tobacco use was
assessed by the admitting physician following direct inter-
view with the patient: any current or history of use was
considered positive. History of previous MI and stroke were
collected from the National Inpatient Registry. A MI was
deﬁned according to the ICD-8 from 1976 through
December 1993 as code 410, and from 1993 onwards ac-
cording to the ICD-10 as codes I21eI22. Stroke was deﬁned
by ICD-8 codes 430e436, excluding transient ischemic
attack, and ICD10 codes I60-I62.
Living status (deceased or alive) as per 15 February, June
2012, was obtained. Date of death was recorded for
deceased patients. From the Danish National Inpatient
Registry, diagnoses of patients and controls were gathered
from the start of the registry in 1976 to 15 February 2012.Prescription information
Data regarding medical therapy was obtained from the
Danish Registry of Medicinal Product Statistics andidentiﬁed on the basis of Anatomical Therapeutical Chem-
ical (ATC) classiﬁcation system. Regular use was deﬁned as
two prescription fulﬁllments within 90 days after operative
treatment. Medical therapy included the following antith-
rombotic agents: acetylsalicylic acid (B01AC06), clopidogrel
(B01AC04), dipyridamole (B01AC07), and warfarin
(B01AA03), or any combination thereof. Registered therapy
also included statin treatment/HMG CoA reductase in-
hibitors (C10AA), diuretics (C03), calcium channel blockers
(C08), angiotensin converting enzyme (ACE) inhibitors and
angiotensin II receptor blockers (ARB) (C09), and beta
blockers (C07).
Endpoints
The primary end points were the ﬁrst incidence of MI,
stroke, or death, each as an individual end point, from the
day of operation, and the combined endpoint, any major
adverse cardiovascular event (MACE), that is either MI,
stroke, or death, whichever occurred ﬁrst.
Statistical analysis
Data are presented as means with standard deviations
(SD), which were compared using the two-sample t test,
and proportions (percentages), which were compared us-
ing the chi-square test. Survival data were analyzed using
the KaplaneMeier method, while the log rank test was
used to test for differences between groups. The Cox
proportional hazards model was used to assess hazard
ratios and 95% conﬁdence intervals (CI), unadjusted and
stratiﬁed by sex and then adjusted for the following: age,
body mass index (BMI), diabetes mellitus, hypertension,
tobacco use, creatinine, pulmonary disease, prior MI, prior
stroke, and prophylactic medication, as described above.
Missing data were as follows: creatinine, 6.0% (n ¼ 676),
body mass index, 24% (n ¼ 2,656), hypertension, 2.1%
(n ¼ 237), diabetes mellitus, 1.1% (n ¼ 122), tobacco, 3.3%
(n ¼ 367), and pulmonary disease, 1.5% (n ¼ 163). Age and
BMI were normally distributed, while creatinine values
were ﬁrst log-transformed in order to obtain normal dis-
tribution. Missing data are accounted for in the Cox pro-
portional hazards model by either applying the median
value for any missing continuous data, or creating a
separate group for missing categorical data. Patients in
each analysis were followed to an event, or censored, if
death occurred (unless death was the endpoint analyzed).
The two sided value of p < .05 was considered to be
signiﬁcant. Analysis was performed with STATA, version
13SE (STATA Corp., TX, USA) and SPSS, version 21 (SPSS
Inc., Chicago, IL, USA).
RESULTS
A total of 11,234 patients were included in the study period.
There were 6,289 (56.0%) male and 4,945 (44%) female
patients. The mean age was 67.8 (SD, 10.5) years for male
patients and 70.8 (SD, 10.7) years for females. See Table 1
for further patient demographics as well as indications for
surgery and 30 day mortality. Table 2 presents the number
Table 1. Baseline patient characteristics and indications for surgery.
Male patients (n ¼ 6,289) Female patients (n ¼ 4,945) p
Age (years) 67.8  10.5 70.8  10.7 <.001a
BMI (kg/m2) 25.4  4.2 23.7  4.7 <.001a
Creatinine (mmol/L) 109  81 89  56 <.001a
Smoking, n (%) 5,454 (86.7) 3,934 (79.6) <.001b
Hypertension, n (%) 2,940 (46.7) 2,637 (53.3) <.001b
Diabetes mellitus, n (%) 1,604 (25.5) 877 (17.7) <.001b
Pulmonary disease, n (%) 997 (15.9) 856 (17.3) .04b
Previous MI, n (%) 1,265 (20.1) 677 (13.7) <.001b
Previous stroke, n (%) 856 (13.6) 589 (11.9) .008b
Acute ischemia, n (%) 487 (7.7) 328 (6.6) <.001b
Claudication, n (%) 2,217 (35.3) 1,698 (34.3) <.001b
Rest pain, n (%) 1,311 (20.8) 1,270 (25.7) <.001b
Gangrene, n (%)
30 day mortality, n (%)
2,274 (36.1)
232 (3.7)
1,649 (33.3)
180 (3.6)
<.001b
.89b
Note. Values are mean  standard deviation. BMI ¼ body mass index; MI ¼ myocardial infarction.
a Two-sample t test.
b Chi-square test.
Table 2. Number of procedures performed per year based on sex.
Total 2000 2001 2002 2003 2004 2005 2006 2007
Patients, n 11,234 1,508 1,444 1,323 1,401 1,436 1,403 1,397 1,322
Men, n (%) 6,289 (56.0) 832 (55.2) 803 (55.6) 723 (54.6) 796 (56.8) 813 (56.6) 766 (54.6) 807 (57.8) 749 (56.7)
Women, n (%) 4945 (44.0) 676 (44.8) 641 (44.4) 600 (45.4) 605 (43.2) 623 (43.4) 637 (45.4) 590 (42.2) 573 (43.3)
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number of procedures performed fell gradually from 1,508
in 2000 to 1,322 in 2007.
Data regarding medication are given in Table 3. There
were no signiﬁcant differences in the use of statins or beta
blockers, while differences between men and women were
noted for antithrombotics, as well as calcium channel
blockers, ACE inhibitors/ARBs, and diuretics.
Maximum follow up was 12.3 years. The overall mean
follow up (to death) was 5.2 years (SD, 3.3) for men and 5.4
years (SD, 3.3) for women. Mean follow up durations for the
individual procedures, as estimated from Kaplan-Meier
curves are given in Table 4.Table 3. Pre-operative medication for male and female patients.
Male patients
(n ¼ 6,289)
Female patients
(n ¼ 4,945)
pa
Statin,
n (%)
3,917 (62.3) 3,067 (62.0) .77
Antithrombotic,
n (%)
4,976 (79.1) 4,011 (81.1) <.001
Beta blocker,
n (%)
2,216 (35.2) 1,745 (35.3) .954
CCB,
n (%)
2,168 (34.5) 2,004 (40.5) < .001
ACE inhibitor/ARB,
n (%)
3,342 (53.1) 2,480 (50.2) < .002
Diuretic,
n (%)
3,383 (53.8) 3,184 (64.4) <.001
ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin II
receptor blocker; CCB ¼ calcium channel blockers.
a Chi-square test.Mortality
Overall, there were a total of 6,407 deaths in the follow up
period: 2,800 among women and 3,607 among men.
KaplaneMeier curves (Fig. 1, upper left) shows that mor-
tality is signiﬁcantly increased in male patients (log-rank
p ¼ .04). The overall hazard ratio for men undergoing sur-
gery for peripheral atherosclerotic disease, as compared to
women, for death was 1.05 (95% CI 1.00e1.11) and 1.11
(95% CI 1.06e1.17) after adjustment.Myocardial infarction
There were 1,496 MIs: among 588 women and 908 men.
KaplaneMeier curves (Fig 1, upper right) showed a signiﬁ-
cantly increased incidence of MI in male patients (log-rank
p ¼ .001). The overall hazard ratio for men, as compared toTable 4. Mean survival times, given in years, based on Kaplane
Meier estimates for sex and procedure.
Male patients
(n ¼ 6,289)
Female patients
(n ¼ 4,945)
Log
rank p
Overall 6.6  0.06 6.8  0.07 .04
Aorto-iliac
procedures
8.2  0.13 8.3  0.13 .55
Femoral artery
procedures
7.2  0.16 6.7  0.20 .12
Femoroefemoral
crossover bypass
6.7  0.16 6.9  0.16 .63
Infrainguinal
bypass
5.9  0.08 6.1  0.10 .29
Axillo-femoral
bypass
3.3  0.36 4.9  0.34 .01
Figure 1. KaplaneMeier curves comparing death (upper left), myocardial infarction (MI) (upper right), stroke (lower left), and MACE (major
adverse cardiovascular event) (lower right) between male and female patients surgically treated for peripheral arterial disease.
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CI 1.04e1.29) after adjustment.Stroke
There were 1,446 strokes among 621 women and 825 men.
Kaplan-Meier curves (Fig. 1, lower left) showed no signiﬁ-
cant difference in the incidence of stroke between men and
women operated on for PAD (log-rank p ¼ .14). The overall
adjusted hazard ratio for men, as compared to women, for
stroke was 1.08 (95% CI 0.98e1.20) and 0.99 (95% CI 0.89e
1.11) after adjustment.Figure 2. Forest plot showing the adjusted hazard ratios (HR) for
death, myocardial infarction (MI), stroke, and MACE (major
adverse cardiovascular event) between male and female patients
operated on for peripheral arterial disease. The 95% conﬁdence
intervals (CI) are provided to the right of each endpoint.MACE
For the combined endpoint MACE, there were 7,195 events
among 3,092 women and 4,103 men. KaplaneMeier curves
(Fig. 1, lower right) showed a signiﬁcantly increased inci-
dence of MACE in male patients (log-rank p ¼ .001). The
overall adjusted hazard ratio for men, compared with
women, for MACE was 1.11 (95% CI 1.06e1.17) and 1.10
(95% CI 1.05e1.16) after adjustment.
The adjusted hazard ratios for the four endpoints are
provided in Fig. 2, while speciﬁc data per procedure be-
tween men and women are detailed in Table 5. Finally, the
30 day mortality for all procedures and patients are
included in Table 1.DISCUSSION
These ﬁndings show that survival, stroke, and MI following
open surgery for PAD are worse for men than women. This
appears true for both central aorto-iliac procedures, as well
as peripheral in situ bypass procedures. There are no sig-
niﬁcant differences in 30 day mortality between women
and men. Although there is a gradual decline in the number
of open surgical procedures, as given in Table 2, the
Table 5. Adjusted hazard ratios for all endpoints per procedure.
Death, HR (95% CI) MI, HR (95% CI) Stroke, HR (95% CI) MACE, HR (95% CI)
All procedures 1.11 (1.06e1.17) 1.16 (1.04e1.29) 0.99 (0.89e1.11) 1.10 (1.05e1.16)
Aorto-iliac procedures 1.16 (1.03e1.34) 1.15 (0.87e1.52) 1.07 (0.82e1.40) 1.16 (1.03e1.31)
Femoral artery procedures 1.16 (0.98e1.37) 1.37 (0.99e1.89) 0.86 (0.68e1.38) 1.15 (0.99e1.34)
Femoro-femoral crossover 1.07 (0.93e1.23) 1.16 (0.84e1.59) 0.84 (0.63e1.13) 1.06 (0.93e1.21)
Infrainguinal bypass 1.11 (1.03e1.19) 1.08 (0.93e1.25) 1.02 (0.87e1.19) 1.09 (1.01e1.17)
Axillo-femoral bypass 1.18 (0.82e1.72) 0.66 (0.25e1.73) 1.96 (0.88e4.32) 1.34 (0.94e1.90)
Note. Female patients are the reference value of 1.0. Multifactorial adjusted for age, surgical indication, body mass index, diabetes
mellitus, hypertension, tobacco use, creatinine, pulmonary disease, previous MI, previous stroke, and the following medical treatment:
statins, ACE inhibitors/ARBs, CCBs, beta blockers, and antithrombotic therapy. ACE ¼ angiotensin converting enzyme;
ARB ¼ angiotensin II receptor blocker; CCB ¼ calcium channel blocker; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular
event; MI ¼ myocardial infarction.
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changed. It is also interesting to note in Table 4 that long-
term survival is greater for both sexes following aorto-iliac
bypass surgery compared with femoro-femoral cross-over
bypass surgery. Although these procedures treat a similar
anatomic segment, the greater survival following aortic
surgery probably reﬂects and conﬁrms the pre-operative
considerations of the patient’s tolerance to the procedure,
as well as long-term prognosis.
There are several issues regarding PAD and sex. First, PAD
is increasing worldwide, while it appears that women are
bearing the burden; the age dependent prevalence of PAD
among women is perhaps lower than for men, yet the total
population burden is greater.4,7e9
Second, symptoms and quality of life may be affected
differently between the sexes. According to a Swedish
study, it appears that asymptomatic PAD is higher among
women, while the inherent cardiovascular morbidity and
mortality is by no means mitigated.10 Women also tend to
have more “atypical” symptoms, just as functional decline is
greater for women than it is for men.11,12 How these affect
eventual treatment and outcomes is not clear but could
potentially play a role, perhaps similar to hypothesized ex-
planations for prognostic differences between men and
women following MI.13
Third, outcomes following treatments may differ, yet
working out if or why this is so poses both practical and
interpretive challenges. Magnant et al.14 reported lower
primary and secondary infrainguinal bypass patencies
among female patients, but this has been contradicted by
other studies.15 Belkin et al.16 found a lower peri-operative
mortality among women undergoing in-situ bypass opera-
tions, further supported by Hultgren et al.,17 who found
that female sex was not an important risk factor for either
amputation or survival. These issues are often complicated
by confounders such as age and various comorbidities such
as diabetes, which, in themselves may be impacted by sex.
Finally, there is an issue of whether patients with PAD
receive recommended optimal medical therapy. Guidelines
regarding medical treatment for PAD are well described and
include statins, antiplatelet medication, and antihyperten-
sive therapy.18e20 Previous studies have indicated that
many patients do not receive this “optimal medical ther-
apy”, particularly patient groups such as women and elderly
people, although this gap may be closing.21With these issues in mind, it is important to consider
what the ﬁndings reveal, particularly when recalling the size
of the study population and the number of adjustments
made in the analysis. It was found that men fare worse than
women when undergoing treatment for peripheral arterial
disease. This is true for the overall results, but also for many
of the subgroups as seen in Table 5. The hazard ratios are
also supported by the average survivals given in Table 4,
which, in general, show greater survival for female patients.
Some of this is driven by the large difference shown in the
axillo-femoral procedures, despite the comparatively fewer
patients in this subgroup. These patients often have
considerable comorbidities, limiting their therapeutic op-
tions, and it is therefore interesting to note that it is here
where a large difference appears between male and female
patients. Why this is so cannot immediately be explained
from the data.
As mentioned above, the ﬁndings stand in contrast to
several other studies, where women either fared similarly
or worse than men in terms of cardiovascular mortal-
ity14,22e24 Magnant et al.,14 showed worse three year sur-
vivals (54% vs. 72%) for women than men following
infrainguinal bypass surgery. Egorova et al.22 likewise
showed worse mortality rates for women following inter-
ventional treatment for PAD, particularly after open sur-
gery. Many although not all studies were from a single
institution. The patients here are a national cohort and bear
the characteristics of typical PAD patients: high levels of
hypertension and tobacco use, as well as substantial
numbers of previous MIs and strokes. The percentage of
smokers is notably greater among men, which perhaps plays
an underlying role in the differences in cardiovascular out-
comes. Prophylactic medical therapy is respectable in the
group, although not optimal. Actual compliance is obviously
difﬁcult to ascertain, gauged by fulﬁllment of two pre-
scriptions within 90 days following operative treatment.
There may be unobserved compliance differences between
men and women that could also partially explain the results
obtained. As to why women have better outcomes among
Danish patients cannot be exacted from the data presented,
although it is interesting that these ﬁndings are to some
degree comparable to those reported by Hultgren et al. in
their study among Swedish patients.17 Another recent study
from Sweden reported a better adjusted prognosis for
women than men following acute MI, which, in their
772 J.W. Budtz-Lilly et al.discussion, may be related to the social and political
milieu.25 Speculations aside, these data do contradict the
possible proposition that there is an inherent or possible
biological basis that women should fare worse in the
treatment of PAD.
There are several limitations to the study. It is retro-
spective, and therefore there are certain inherent biases at
play. The data are dependent on reliable data recording. As
mentioned above, the national Danish vascular surgery
database has been validated on two occasions and should
minimize this risk. Selection bias is also a concern. The large
data pool and patient demographic similarities should
mitigate some of this bias. There is also a question of data
generalizability. The study is nationwide, but some patients
were not included. Patients who underwent endovascular
treatment, for example, were not included. There is no
question that the number of endovascular procedures is
increasing, further evidenced by the decline in the number
of open surgical procedures in Table 2. Whether there is a
difference in the offering of endovascular treatment for
men or women cannot be ascertained from these data, but
this lack of accounting may affect the conclusions. It is
important to note, however, that the ratio between men
and women did not change in the period under analysis.
The decision not to include endovascular procedures was
deliberate, however, mostly out of a concern for further
confounding. True, newer therapies, such as drug eluting
balloons/stents could potentially affect long-term patency
and other outcomes in patients, even though the underly-
ing cardiovascular risk proﬁle is unchanged, but this is un-
known. Evolving treatment is an issue for any retrospective
analysis.
To that end, it is important to reiterate that any vascular
therapy should take several factors into account when
addressing outcomes, including patency, amputation rates,
and quality of life. The authors chose to look at the long-
term cardiovascular burden in patients with PAD to see if
there is a difference between men and women, despite
revascularization and best medical therapy.CONCLUSION
These ﬁndings show that, despite indication, severity, and
concomitant medical treatment of peripheral artery dis-
ease, men have a higher risk of mortality and adverse car-
diovascular events following surgical treatment.CONFLICT OF INTEREST
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